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Germline mutations of the LKB1 (STK11 ) tumor suppressor gene lead to Peutz-Jeghers syndrome (PJS) and
predisposition to cancer. LKB1 encodes a serine/threonine kinase generally inactivated in PJS patients. We
identified the dual phosphatase and tumor suppressor protein PTEN as an LKB1-interacting protein. Several
LKB1 point mutations associated with PJS disrupt the interaction with PTEN suggesting that the loss of this
interaction might contribute to PJS. Although PTEN and LKB1 are predominantly cytoplasmic and nuclear,
respectively, their interaction leads to a cytoplasmic relocalization of LKB1. In addition, we show that
PTEN is a substrate of the kinase LKB1 in vitro. As PTEN is a dual phosphatase mutated in autosomal inhe-
rited disorders with phenotypes similar to those of PJS (Bannayan–Riley–Ruvalcaba syndrome and Cowden
disease), our study suggests a functional link between the proteins involved in different hamartomatous
polyposis syndromes and emphasizes the central role played by LKB1 as a tumor suppressor in the small
intestine.
INTRODUCTION
Syndromes with Mendelian modes of inheritance that predis-
pose to cancers provide excellent opportunities to discover
genes implicated in cancer and thus contribute to an under-
standing of the regulation of cell division. The Peutz-Jeghers
syndrome (PJS) is an autosomal dominant disease characte-
rized by mucocutaneous pigmentation and gastrointestinal
hamartomatous polyposis (OMIM no. 175200). PJS patients
are at an increased risk to develop malignancies, and the
organs that are most targeted are the gastrointestinal tract,
breasts and female reproductive organs (1,2). The genetic
locus responsible for the majority of PJS cases was mapped
to chromosome 19p13.3 and found to encode a serine/threonine
protein kinase named LKB1 (alias STK11) (3–5). The
mutations lead to loss or impairment of kinase activity (6,7).
Transfection of LKB1 into human tumor cell lines having
reduced levels of LKB1 mRNA or impaired LKB1 kinase
activity results in a G1 cell cycle arrest (8). This growth
inhibitory effect is mediated through signaling of cytoplasmic
LKB1 and induction of p21 expression through a p53-dependent
mechanism (9).
Lkb1-deficient mice (Lkb12/2) die as embryos displaying
neural tube defects, mesenchymal cell death, vascular abnorm-
alities with severe extra-embryonic development and overex-
pression of vascular endothelial growth factor (VEGF) (10).
Heterozygous Lkb1 knockout mice develop hamartomatous
polyps in the gastrointestinal tract without inactivation of
the remaining wild-type Lkb1 allele, suggesting that polyposis
results from LKB1 haplo-insufficiency (11), rather than LOH
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(3). Genetic studies revealed that LKB1 orthologues are
required to establish embryonal polarity in Drosophila
melanogaster, Caenohabditis elegans and Xenopus (12–14).
Interestingly, cell polarity is severely compromised in a
variety of human cancers but it remains unclear whether loss
of polarity is a consequence of uncontrolled proliferation or
a causative factor in cancer initiation. Most knowledge
about cell polarity mechanisms has been generated in studies
using simple, genetically tractable organisms including
Drosophila, C. elegans and yeast (15). However, genes
responsible for cell polarity also regulate cell proliferation in
these organisms. Although, LKB1 has been connected
through protein–protein interaction to several pathways that
influence cell proliferation (16–19), it is not known
whether tumorigenesis in human LKB1 mutants is, indeed,
influenced by polarity abnormalities. Recently endogenous
complexes of human LKB1 with two proteins, STRAD and
MO25a were identified and shown to regulate epithelial
polarity. This suggested a model in which loss of LKB1 in
humans may cause cellular transformation through disruption
of epithelial polarity (20). However, expression of STRAD
and MO25a has not been directly demonstrated in the
gastro-intestinal organs except for pancreas and liver (21).
Hence, the genuine substrate of LKB1 in the gastrointestinal
tract, where the PJS phenotype is the strongest resulting
in hamartomatous polyps and/or cancer, remains to be
identified.
To further assess the biological function of the kinase
LKB1, we performed a two-hybrid selection in yeast. We
identified the tumor-suppressor protein PTEN as an LKB1-
interactor. PTEN is frequently mutated in a large number of
cancers but also in other autosomal dominant diseases such
as Cowden disease (CD) and Bannayan–Riley–Ruvalcaba
syndrome (BRRS) (22), both belonging to the same family
of hamartomatous polyposis syndromes as the PJS. We
confirmed this interaction in mammalian cells and found that
PTEN overexpression in cells results in the cytoplasmic reten-
tion of LKB1. Moreover, we identified PTEN as a substrate of
the kinase LKB1 in vitro.
RESULTS
Isolation of PTEN in a yeast two-hybrid selection
of LKB1 interactors
The 313 N-terminal amino acids of LKB1 (LKB1-313)
comprising the kinase domain were used to screen a human
testis cDNA library by the yeast two-hybrid method
(Fig. 1A). The rationale for this choice was that most of the
natural PJS mutations map to this domain and that no transac-
tivation was observed in yeast with this construct. One LKB1-
interacting clone contained almost the entire coding sequence
(from codon 39) of the dual phosphatase and tumor suppressor
PTEN (Fig. 1B; PTEN39-403) (22). This partial PTEN clone
does not contain the minimal domain required for the inter-
action with phospholipids (PIP2 domain, Fig. 1B) (23). To
map the minimal LKB1-interaction domain of PTEN, we gen-
erated a series of truncated PTEN fusions (Fig. 1B) and tested
them for interaction in two different yeast strains (Y190 and
PJ69-4A; see Materials and Methods): (i) two C-terminal
deletions of PTEN (PTEN39-314 and PTEN39-224, larger
deletions were unstable in yeast), (ii) one N-terminal deletion
(PTEN173-403) that preserves the integrity of the C2 domain
(24) and (iii) a deletion of the phosphatase active site
(PTEN39-403DAS, deletion of residues 122 to 131,
Fig. 1A). The results of these interaction mating experiments
are shown schematically in Figure 1B. Most notably, the
PTEN AA 173-403 fusions are sufficient for interaction with
LKB1. These data suggest that the minimal LKB1-interaction
domain may include the N-terminal portion of the PTEN C2
domain (see subsequently). We also tested two truncated
fusions of LKB1 for interaction with PTEN39-403 and
found that the kinase domain (LKB49-309) was sufficient
for this interaction (Fig. 1A).
Influence of pathogenic LKB1 and PTEN missense
mutations on the interaction
We used the yeast two-hybrid system to determine the effects
of pathogenic LKB1 or PTEN missense mutations on the
LKB1–PTEN interaction. The tested mutations are shown in
Figure 1. For LKB1, they comprised three germline missense
mutations causing PJS (L67P, D176N and W308C), one
somatic mutation found in a testicular carcinoma (G163D)
and an engineered mutation that affects the ATP-binding site
of LKB1 (K78I) (2,4,6,25). The LKB1 amino acid substitution
mutants L67P, K78I, D176N and W308C and G163D have
previously been reported to be kinase-defective or partially
defective, respectively (6,25). Remarkably, K78I and D176N
maintained the interaction with PTEN, whereas the other
kinase-defective mutants L67P and W308C, as well as
G163D, lost the capability of interacting with PTEN. These
results demonstrate that the LKB1 kinase activity is not
necessary for binding to PTEN and suggest the possibility
that the pathogenicity of some mutations is not solely due to
impaired LKB1 kinase activity but also due to decreased affi-
nity for PTEN.
For PTEN, we tested two germline mutations causing
Cowden syndrome (C124R, G129E), a somatic mutation
found in the glioma cell line U343MG (C124S) and one spora-
dic mutation causing Bannayan–Riley–Ruvalcaba syndrome
(C105Y) (26–29). The PTEN point mutations C124R,
C124S and G129E are defective in either both protein and
lipid phosphatase (C124R/S), the lipid phosphatase (G129E)
activity or in both the lipid and the protein phosphatase
(C124R/G129E) activities (30–33). In the context of the
PTEN39-403 protein, none of these PTEN point mutants nor
the deletion mutant PTEN39-403DAS showed interaction
with LKB1 (Fig. 1B), demonstrating that the N-terminal
portion of the PTEN C2-domain (discussed earlier) is either
not sufficient for interaction with LKB1 or that a structurally
destabilized phosphatase domain interferes with its inter-
action. Taken together, these results suggest that the LKB1–
PTEN interaction requires the N-terminal portion of the
PTEN C2-domain and, in the context of the full-length
protein, the integrity of the phosphatase domain. We also
tested the PTEN39-403T382A/T383A double mutant,
because phosphorylation at these residues regulates PTEN
stability and function in mammalian cells (34). This double
mutant is still capable of interacting with LKB1 (Fig. 1B).
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PTEN interacts with LKB1 in mammalian cells
and influences its subcellular localization
To confirm the interaction between LKB1 and PTEN in
mammalian cells, co-immunoprecipitation experiments were
carried out both with exogenously overexpressed and with
endogenous proteins. For the former, COS7 cells were transi-
ently transfected with plasmids expressing LKB1 fused to myc
and GFP tags and PTEN fused to a V5 epitope (Fig. 2).
Lysates were immunoprecipitated with V5-antibodies and
probed with anti-LKB1 or anti-PTEN specific antibodies
(Figs. 2A and B). LKB1 was exclusively precipitated in the
presence of PTEN, demonstrating that LKB1 and PTEN can
interact in mammalian cells.
To assess whether endogenous LKB1 and PTEN interact,
we used 5 mg of a total protein extract from normal
human small intestine and immunoprecipitated endogenous
PTEN using anti-PTEN antibodies. Fifty microgram of the
total extract was loaded as input (lysate) for comparison
and immunoblots were probed with anti-LKB1 antibodies.
We found a single band that co-precipitated with PTEN
with the same size as LKB1 in total human small intestine
extract (Fig. 2B) but not in the control immunoprecipitation
with a control antibody of the same isotype. Likewise,
anti-PTEN antibodies showed that PTEN was only precipi-
tated with the corresponding antibody (Fig. 2B). Hence, we
conclude that endogenous LKB1 physically interacts with
PTEN.
Figure 1. LKB1 and PTEN interactions in yeast two-hybrid assays. Schematic representation of LKB1 and PTEN constructs used in this study. (A) LKB1 and
(B) PTEN proteins and their derivatives were tested for interaction with PTEN 39-403 and LKB1 1-313, respectively, in two different yeast strains (Y190, right
column and PJ69-4A, far right column). A ‘þ ’ sign denotes interaction, whereas a ‘2 ’ sign denotes no interaction. DAS, deleted active site.
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When overexpressed, an HA-tagged LKB1 localizes predo-
minantly in the nucleus (78% in COS7 and 64% in U2OS)
(Fig. 3A, D and E). In contrast, the Myc-EGFP–PTEN
fusion protein, referred to as GFP–PTEN, shows a more cyto-
plasmic localization (59% in COS7 and 87% in U2OS cells)
(Fig. 3A–C). These results are in accordance with previously
published analyses (16,35–38). Because of the previous-
described difference in subcellular localization of the two
proteins, we tested the consequences of the LKB1 and
PTEN interaction on the localization of both proteins upon
co-expression. Interestingly, co-expression of GFP–PTEN
and HA-LKB1 resulted in the accumulation of LKB1 in the
cytoplasm. Upon co-expression, the number of cells showing
mainly cytoplasmic localization of HA-LKB1 increased
from 22 to 58% in COS7 cells and from 36 to 60% in
U2OS cells (P , 0.0001) (Fig. 3D and E). In contrast, co-
expression of epitope-tagged LKB1 had less dramatic effects
on the cellular localization of GFP–PTEN (Fig. 3B and C),
although we did note a subtle cytoplasmic relocalization of
PTEN in COS7 cells. The cytoplasmic relocalization of
epitope-tagged LKB1 is specific to PTEN co-expression, as
HA-LKB1 remained predominantly nuclear when the GFP
tag by itself was co-expressed (Fig. 3D and E). The C-terminal
deletion mutant of PTEN (PTEN314), which still interacted
with LKB1 in the two-hybrid assay (Fig. 1B), produced a cyto-
plasmic relocalization of LKB1 that was not significantly
different from that affected by wild-type PTEN (P ¼ 0.1;
Fig. 3D and E). These results show that PTEN influences
the subcellular localization of LKB1, possibly by retaining it
in the cytoplasm.
Next, we determined the influence of PTEN on the localiz-
ation of two known LKB1 mutants: D176N and G163D, of
which we have shown the latter to be defective for interaction
with PTEN in the yeast two-hybrid system (Fig. 1A). D176N
is known to have a nucleo-cytoplasmic distribution similar to
that of wild-type LKB1, whereas G163D is predominantly
nuclear (Fig. 3F). Interestingly, PTEN could only affect the
localization of D176N (P , 0.001) but not that of the non-
interacting mutant G163D (Fig. 3F).
LKB1 phosphorylates PTEN in vitro
To explore the functional consequences of the interaction of
LKB1 and PTEN, we first examined whether PTEN is an
LKB1 phosphatase. Although we cannot formally rule out
this possibility, we were not able to find any evidence for it
(data not shown). Next, we carried out in vitro kinase assays
to assess whether LKB1 phosphorylates PTEN. We used
purified PTEN expressed as a thioredoxin fusion protein in
bacteria as a substrate for wild-type LKB1, or for the
kinase-dead LKB1 mutant D176N, immunoprecipitated from
transfected HEK293 cells. We found that immunoprecipi-
tated LKB1 phosphorylates recombinant PTEN, but not the
thioredoxin tag alone (Fig. 4; compare lanes 1 and 2). This
phosphorylation is due to LKB1 rather than another co-
immunoprecipitating kinase activity as the immunoprecipitate
of the kinase-defective mutant D176N fails to phosphorylate
the recombinant PTEN (Fig. 4; compare lanes 1 and 3).
Phosphorylation of PTEN by LKB1 depends on a cluster
of residues preceding and encompassing S385
To pinpoint the residues of PTEN that are phosphorylated by
LKB1, and because the C-terminus of PTEN contains many
potential phosphorylation sites, we split PTEN into two frag-
ments (amino acids 1–314 and amino acids 314–403).
We found that only the C-terminal fragment (PTEN314-403)
is phosphorylated (Fig. 5) (data not shown). Within this
Figure 2. Biochemical evidence for the interaction of LKB1 with PTEN. (A)
Exogenously expressed LKB1 and PTEN interact in COS7 cells. The two
proteins were transiently co-expressed from plasmids pcDNA3–myc-EGFP
and pcDNA–V5. 500 mg of each lysate were immunoprecipitated with an
anti-V5 antibody (Invitrogen). Immunoprecipitates were subjected to immuno-
blot analysis with anti-LKB1 antibodies (top) or with anti-PTEN antibodies
(bottom). The upper arrow (‘LKB1’) indicates the band corresponding to
the fusion protein myc-EGFP–LKB1 coprecipitated with the fusion protein
PTEN–V5 (‘PTEN’). IgH indicates the antibody heavy chain. The micro-
graphs are representative of an experiment done in triplicate. (B) Endogenous
LKB1 and PTEN interact in human small intestinal tissue. 5 mg of a total
protein lysate from normal human small intestine were immunoprecipitated
with anti-PTEN antibodies. Immunoprecipitates were submitted to immuno-
blot analysis with anti-PTEN (top) and anti-LKB1 antibodies (bottom).
Lysate, 50 mg of the input lysate.
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C-terminal fragment, we then decided to focus on a cluster of
serine and threonine residues between S360 and S385
(Fig. 5A), which includes predicted and demonstrated phos-
phorylation sites (39–41). We mutated the corresponding
codons in sets and individually and determined phosphory-
lation of the mutants as described earlier for the wild-type frag-
ment. Experiments summarized in Figure 5A established that
all single mutants and the multiple mutants A6 and even A3,
which combines S380A, T382A and T383A, could still be
phosphorylated. In contrast, phosphorylation was abolished
when S385A was combined with any of the single mutants
between S380 and T383 (mutants A4, A2A, A2B and A2C).
Thus, S385 becomes critical whenever one of the potential
phosphorylation sites between S380 and T383 is mutated.
These results point to these four serine/threonine residues as
the most likely phosphorylation sites, but also indicate a rela-
tively complex mechanism that may involve distinct recog-
nition and possibly cooperative phosphorylation steps.
Figure 3. PTEN influences the subcellular localization of LKB1. (A) Typical examples of the subcellular localization patterns of transiently expressed
myc-EGFP (GFP), myc-EGFP–PTEN (GFP–PTEN) and HA-LKB1 (LKB1). (B) and (C) The effects of LKB1 co-expression on the localization of PTEN
in COS7 and U2OS cells, respectively. Results are indicated as the percentage of cells showing either mostly cytoplasmic or mostly nuclear fluorescence
(see color-coded legend). The effects of PTEN co-expression are statistically highly significant (P, 0.0001). (D) and (E) The effects of overexpression of
wild-type or C-terminally truncated PTEN on the localization of LKB1 in COS7 and U2OS cells, respectively, as determined by immunofluorescence with
an antibody against the HA tag. Statistical comparison showed that there is no significant difference between wild-type PTEN and PTEN314 (P ¼ 0.10) on
the localization of LKB1. (F) Influence of PTEN overexpression on the localization of LKB1 point mutants G163D and D176N in COS7 cells. Statistically
wild-type PTEN has the same effect on D176N as on wild-type LKB1 (P, 0.0001) but not on the mutant G163D (P . 0.05). Equal amounts of both
LKB1 and PTEN expression vectors were cotransfected and about 120 labeled cells were counted. Individual panels represent separate experiments with repli-
cates. Thus, absolute numbers for a given sample may vary between panels. Most bars represent averages of multiple independent replicates, but error bars have
been omitted for clarity (standard errors were typically 5%).
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DISCUSSION
We have demonstrated a functional link between LKB1 and
PTEN, whose genes are both mutated in different but related
autosomal dominant hamartomatous polyposis syndromes.
Although LKB1 is mutated in PJS, germline mutations in
PTEN are the genetic cause not only for CD but also for
another hamartomatous polyposis syndrome, the BRRS. The
PTEN tumor suppressor gene encodes the first identified phos-
phatase that is frequently mutated or deleted somatically in
various human cancers (26,28). PTEN can dephosphorylate
phospho-tyrosine, -serine and -threonine peptides in vitro
(30). However, the predominant enzymatic activity of PTEN
appears to be the dephosphorylation of the phosphoinositide
PIP3, a product of phosphatidylinositol-3-kinase (PI3K),
which is required for the phosphorylation and activation of
PKB/Akt, a survival factor protecting many cell types
against apoptosis (23,24,30,42–44).
Our finding that PTEN is an LKB1-interactor is particularly
interesting as it provides the first direct evidence that these two
tumor suppressors are involved in a common pathway. This
is consistent with several previous observations: (i) The
expression patterns of both genes overlap significantly (7);
(ii) a cDNA microarray study with the Lkb1-deficient lung
cancer cell line A549 revealed an upregulation of PTEN
upon transient re-expression of LKB1 (45); (iii) the lethal
phenotypes of Lkb12/2 and Pten2/2 mice share some fea-
tures (46); (iv) both types of null homozygous mice die at a
similar stage of embryonic development and homozygous
mutations in both genes induce dysregulation of VEGF
(10,47); (v) growth-suppressive effects of LKB1 or PTEN
overexpression are limited to LKB1 or PTEN-deficient cells,
respectively (8,48,49).
The kinase domain of LKB1 is sufficient for binding to
PTEN, but kinase activity per se is not essential. Some
LKB1 mutants are still able to interact with PTEN despite
having an impaired kinase activity (K78I and D176N). The
other tested LKB1 mutants (L67P, G163D and W308C) fail
to bind to PTEN. Among these, G163D retains some kinase
activity. It is tantalizing to speculate that the pathogenicity
of this mutant is due, at least in part, to its decreased affinity
for PTEN and that wild-type LKB1 function depends on the
both interaction and phosphorylation of PTEN. Although the
C2 domain of PTEN is sufficient to interact with LKB1,
mutations in the phosphatase domain abolish the interaction.
The importance of the phosphatase domain is further under-
lined by the observation that a truncated PTEN mutant
lacking the C2 domain (PTEN314) still promotes the subcellu-
lar relocalization of LKB1 (discussed subsequently). Although
the very C-terminus of PTEN is sufficient to serve as a sub-
strate for phosphorylation by LKB1, we speculate that it is
not part of the primary interaction surface and that the cataly-
tic interaction is favored by the in vitro conditions of the
kinase assay. Taken together, all of these results indicate a
complex interplay involving multiple domains of PTEN.
While our data are consistent with the findings of the crystal
structure of PTEN that reveal extensive intramolecular inter-
actions between independently folding phosphatase and
C2 domains (24), further studies will be necessary to clarify
these observations.
One consequence of the interaction is that PTEN overex-
pression leads to increased cytoplasmic accumulation of
LKB1. Unlike the kinase activity, the ability to interact with
PTEN correlates with the subcellular localization of LKB1
mutants. Most of the kinase-defective LKB1 mutants are
concentrated in the nucleus (9,35) and are unable to interact
with PTEN. In contrast, those LKB1 mutants that are partially
cytoplasmic (D176N and K78I) (9,35) also interact with PTEN.
Although we found no evidence that LKB1 is a substrate for
PTEN, this possibility remains to be further explored. Indeed,
many phosphorylation sites have been identified in LKB1
(50), including sites that are phosphorylated by PKA (13)
Figure 4. Recombinant PTEN is phosphorylated by LKB1 in vitro. (A) Auto-
radiography of in vitro kinase assay performed with recombinant substrates
and LKB1 immunoprecipitated from HEK293 cells transfected with plasmid
pcDNA-LKB1-V5. Substrates were a thioredoxin fusion protein of PTEN
(Trx-PTEN) or the thioredoxin tag (Trx tag) alone. Kinases were either the
wild-type LKB1 (wt) or a kinase-defective LKB1 point mutant (D176N).
(B) and (C) Immunoblots illustrating that equal amounts of both substrate
(revealed with an anti-His6 tag antibody) and kinase (anti-V5) were used.
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and one or several of these sites could be targets for PTEN in
its protein phosphatase mode.
Recent analyses identified PTEN residues T366, S370,
S380, T382, T383 and S385 as in vivo phosphorylation sites
(39–41). Phosphorylation of residues S380, T382 and T383
by casein kinase II (CK2) affects PTEN stability and activity
(39,40). The same kinase is responsible for phosphorylation
of residues S370 and S385, whereas another yet unidentified
kinase is likely to phosphorylate T366 (41). We provide
evidence suggesting that LKB1 phosphorylates PTEN at
residue S385 in combination either with S380, T382 or T383.
Thus, the mode of phosphorylation of PTEN by LKB1 is
different from that by CK2. Interestingly, the tumor suppressor
PTEN can inhibit cell migration and this activity depends both
on its protein phosphatase activity and its C2 domain (51).
This activity of the C2 domain is controlled by the phos-
phorylation state of the T383. When phosphorylated by an
unknown kinase, the C2 domain loses its inhibitory effect on
cell migration. LKB1 might be the kinase that phosphorylates
T383 on the basis of our in vitro phosphorylation data and the
fact that both lipid and protein phosphatase domains of PTEN
are required for the interaction. It will be interesting to test the
role of LKB1 in PTEN-regulated cell migration.
In mammalian cell culture, PTEN has been shown to regu-
late cell proliferation and survival via its lipid phosphatase
activity (48,52). It is unlikely that LKB1 has an effect on
cell proliferation and survival through the regulation of the
PTEN lipid phosphatase activity. This statement is based on
the following observations: (i) The PTEN construct that we
found in our yeast two-hybrid screen lacks the first fourteen
amino acids that are required for the binding of PIP2;
(ii) the phosphorylation of AKT is not up-regulated in polyps
of PJS patients and heterozygote Lkb1þ/2 mice; (iii) LKB1
re-expressed in transfected Lkb1-deficient cells does not
affect the levels of phosphorylated AKT (53,54).
Several other proteins have been shown to interact
with LKB1. LKB1 interacts with and phosphorylates p53
(16,21,55). Germline mutations of p53 cause the autosomal
dominant Li-Fraumeni syndrome (OMIM no. 151623), a
cancer syndrome associated with breast cancer, soft tissue
Figure 5. Mapping the PTEN phosphorylation site(s) of LKB1. (A) Schematic representation of the C-terminal 89 residues of PTEN that can be phosphorylated
by LKB1 in vitro. The details of the mutants are shown below the sequence of amino acid 360–403. (B) The results for all tested mutants are summarized.
In vitro kinase assays were performed as described in the legend to Figure 4 and in Materials and Methods, except that the substrate was a thioredoxin
fusion protein encompassing only the 89 C-terminal amino acids (314–403) of PTEN. The left panel is a control experiment demonstrating that the thioredoxin
(Trx) tag of the substrate and the A4 mutant are not phosphorylated by LKB1. Top, middle and bottom panels show the autoradiography (phosphorylated
substrate), the Coomassie-stained gel (total substrate) and the LKB1 immunoblot (kinase), respectively.
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sarcomas, brain tumors, osteosarcoma, leukemia and adreno-
cortical carcinoma. However, patients with Li-Fraumeni
syndrome do not develop hamartomatous polyposis. More-
over, p532/2 mice do not develop small intestinal polyps
during their life span, and eventually die of other types of
cancers. In addition, the phenotypes of either Lkb12/2 or
Pten2/2 mice are completely different from that of p532/2
mice (56). Taken together, these data suggest that p53 may
not be a physiological substrate of LKB1 for the onset of
PJS although it may play a role later in the development of
cancer in PJS patients (57).
It has been suggested that loss of the tumor suppressor
LKB1 may result in cellular transformation as a consequence
of disrupted epithelial polarity (20). In this context, it is
noteworthy that the LKB1 complexes with the two accessory
subunits, STRADa/b and MO25a/b (21), could play a role in
activating AMP-activated kinase (AMPK) in mammalian cells
(58). Moreover, STRAD activates LKB1, which has been
shown to be responsible for cell polarization. The paradox is
that STRAD is not expressed in intestinal epithelial cancer
cell lines (20) nor are there human ESTs or tags corresponding
to STRAD in gastrointestinal tissues. This suggests that
STRAD might not be expressed in gastrointestinal tissues
where the phenotype of PJS is the most expressed as hamarto-
matous polyps and/or cancer, notably in the small intestine,
colorectum and stomach (1). Gene expression studies using
MO25a as a probe have not been done on gastrointestinal
tract tissues (except liver and pancreas where it is expressed)
(21). Thus, although STRAD and MO25a have been demon-
strated to interact with LKB1 in several tissues and cell
lines, this remains to be demonstrated for the human gastroin-
testinal tract. It is also important to point out that polyps in PJS
patients are not only the consequence of proliferation of the
intestinal epithelium but also of smooth muscle cells display-
ing a characteristic pattern called tree-like branches of smooth
muscle, which is an arborizing network of smooth muscle
bundles and the most widely used criterion for establishing
the diagnosis of PJS polyps.
On the basis of its biochemical interaction with the LIP1–
SMAD4 complex, LKB1 has previously been linked to yet
another polyposis syndrome, the Juvenile polyposis syndrome
(PJI) (18). Moreover, LKB1 was found to activate TSC2,
the gene mutated in Tuberous sclerosis, another hamartoma-
tous syndrome, through the AMP-dependent protein kinase
(AMPK) (59). Our finding of PTEN as an LKB1 interacting
protein and substrate provides new evidence for functional
connections among several hamartomatous polyposis syn-
dromes, namely Peutz-Jeghers syndrome, Cowden syndrome,
BRRS, PJI and Tuberous sclerosis.
MATERIALS AND METHODS
Plasmids and mutants
All yeast two-hybrid constructs containing the full-length
cDNA of human LKB1 and its deletion mutants were
expressed from plasmids pGBT9 and/or pGBDU (Clontech).
The inserts were amplified using Pfu DNA polymerase
(Promega) and cloned between EcoRI/PstI sites. For
expression in mammalian cells, LKB1 and PTEN coding
sequences were cloned into pcDNA3-myc-EGFP (pcDNA3
modified to include EGFP with an N-terminal myc-tag) (60)
or pcDNA3-V5 (Invitrogen) or pcDNA-HA. For bacterial
expression, PTEN derivatives encompassing codons 1–314
and 314–403 were subcloned into pET-32Ek/LIC (Novagen)
between EcoRI/XhoI sites. Missense mutations of LKB1 and
PTEN were generated with the Quick-change mutagenesis
kit (Stratagene). The sequences of all of the constructs used
in this study were verified.
Yeast two-hybrid selection
The yeast two-hybrid selection with a human testis cDNA
MatchMaker library (Clontech) was performed in the yeast
strain Y190 (Clontech) using a fusion of the GAL4 DBD
with the N-terminal 313 amino acids of LKB1 (expressed
from plasmid pGBT9-LKB1-313) as a bait. In subsequent
two-hybrid assays, yeast strain PJ69-4A (Clontech) was also
used either interchangeably or for certain bait constructs that
displayed auto-activation in Y190. As judged by Western
blot analysis, different bait and prey fusion proteins were
expressed at similar levels (data not shown).
Cell culture and immunoprecipitation
COS7, U2OS or HEK293 cells (ATCC) were grown at 378C in
5% CO2 and cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum and 1% of penicillin–
streptomycin (100 IU/ml and 100 mg/ml, respectively). Cells
were transfected with plasmids pcDNA3–myc-EGFP–LKB1
and pcDNA3–PTEN–V5 using lipofectin (Life Techno-
logies). Two days later, cells were lysed in 500 ml of ice-
cold lysis buffer [50 mM Tris–HCl pH 8.0, 150 mM NaCl,
1% Triton X-100 containing a protease inhibitor cocktail
(Roche)] and centrifuged for 20 min at 10 000g and 48C.
The supernatant was recovered and precleared for 4 h with
protein G agarose beads (Roche). Subsequently, monoclonal
antibodies to either the myc (Santa Cruz Biotechnology) or
V5 (Invitrogen) tags were incubated with the cell extracts,
and 1 h later the protein G-agarose beads (Roche) were
added and incubated over night at þ48C with shaking. The
agarose beads were pelleted by centrifugation, washed three
times with 1 ml of washing buffer (50 mM Tris–HCl pH 8.0,
150 mM NaCl, 1% Triton X-100) and resuspended in SDS
gel-loading buffer (62 mM Tris–HCl pH 7.4, 2% SDS,
10% glycerol, 5% b-mercaptoethanol) and boiled for 3 min.
After centrifugation the supernatant was subjected to SDS
gel electrophoresis on a 10% SDS–PAGE gel. Proteins were
electro-transferred to nitrocellulose membranes (Hybond,
Amersham Pharmacia). Blots were incubated with 5%
non-fat dry milk in Tris-buffered saline containing 0.05%
Tween-20. To immunoprecipitate endogenous proteins with
antibodies against PTEN, a commercial total protein extract
from human small intestine (Biochain) was used. For immuno-
blotting, antibodies to LKB1 or to PTEN (both from
Santa Cruz Biotechnology) were diluted 1:1000. Horseradish
peroxidase-conjugated donkey anti-goat, mouse anti-goat
(Sigma), anti-mouse antibodies (Santa Cruz Biotechnology)
or goat anti-mouse Kappa light chain antibodies (Bethyl)
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were used. The ECL chemiluminescence system (Amersham-
Pharmacia) was used for detection.
Immunofluorescence
COS7 or U2OS cells were grown on coverslips and fixed
with 3% PFA 24 h after transfection. HA-tagged proteins
were detected using an anti-HA monoclonal antibody at
1:200 (Santa Cruz Biotechnology) and Rhodamine-coupled
anti-mouse secondary antibody (Santa Cruz Biotechnology).
Alternatively, EGFP fusion proteins were used. DNA staining
was carried out with DAPI (Sigma).
Bacterial expression and purification of PTEN
and mutant derivatives
For expression of wild-type and mutant derivatives of PTEN
fused to a His6-thioredoxin tag (Trx-PTEN), Escherichia
coli BL21 transformants were grown in 250 ml of L-broth
at 378C to mid-log phase (A600 nm ¼ 0.6). Isopropyl b-D-
thiogalactopyranoside was added at a concentration of 0.2 mM
the culture was incubated for an additional 6 h at 258C. There-
after, all of the procedures were performed at 48C. The pellets
were resuspended in 5 ml of ice-cold lysis buffer containing
50 mM NaH2PO4 pH 8.0, 500 mM NaCl, 5 mM imidazole,
5 mM b-mercaptoethanol and 1 mM phenylmethylsulfonyl
fluoride (PMSF), and bacteriolysis was performed by soni-
cation until the cell suspension became transparent. After
the addition of 50 ml of Tween-20, the lysate was incubated
on ice for 20 min and then centrifuged at 14 000g for
15 min. The supernatant was mixed with 250 ml of Ni-NTA-
agarose (Qiagen) for 45 min at 48C. The beads were washed
three times with 1 ml of the wash buffer containing 50 mM
NaH2PO4 pH 8.0, 300 mM NaCl and 20 mM imidazole, and
eluted three times with 250 ml of the elution buffer containing
50 mM NaH2PO4 pH 8.0, 300 mM NaCl and 250 mM imidazole.
The buffer of the eluted solution was then replaced with
500 ml of TED buffer containing 20 mM Tris–HCl pH 8.0,
300 mM NaCl, 2 mM EDTA, 2 mM DTT and 1 mM PMSF by
using a Microcon column (Millipore Corporation, Bedfort,
MA, USA) and reduced to a volume of 50 ml. The purified
protein was stored in the presence of 10% (v/v) glycerol at
2808C until use. Protein concentrations and the integrity of
fusion proteins were determined by 10% SDS–PAGE and
by comparison with known concentrations of BSA using
Coomassie blue staining and with western blot using the
anti-His tag antibodies (Sigma).
In vitro LKB1 kinase assays
V5-tagged wild-type and D176N mutant LKB1 were transi-
ently expressed in HEK293 cells. Immunoprecipitation was
carried out with anti-V5 antibodies as described earlier
except that the immunoprecipitates were washed six times
with 1 ml [twice each with: lysis buffer, washing buffer and
kinase buffer (20 mM Tris–HCl pH 7.5, 150 mM KCl,
0.3 mM ATP, 5 mM MgCl2, 0.5 mM dithiothreitol)]. One
microgram of Trx-PTEN fusion protein was incubated with
50 ml of protein G Sepharose beads with immunoprecipitates
of wild-type and mutant (D176N) LKB1 for 30 min at 308C
in kinase buffer (20 mM Tris–HCl pH 7.5, 150 mM KCl,
0.3 mM ATP, 5 mM MgCl2, 0.5 mM dithiothreitol, 50 ml final
volume) containing 2 mCi of g-[32P]ATP per sample. The
reactions were stopped by adding SDS–PAGE sample buffer
and boiling, followed by SDS–PAGE and autoradiography.
Statistical analysis
Comparative analyses of subcellular localizations were done
with Fisher’s exact test and Student’s t-test. A P-value of
,0.05 was considered statistically significant.
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